CAR-T Meeting 2024 | The real-world efficacy of CAR-T cells in post-transplant relapsed B-ALL
Alex Rampotas
• 15 Feb 2024
In this video, Alex Rampotas, MD, University College London, London, UK, discusses a real-world study evaluating the safety and efficacy of CAR-T cells in patients with post-transplant relapsed B-cell acute lymphoblastic leukemia (B-ALL). CAR-T cells resulted in a superior progression-free and overall survival (PFS; OS) in this patient population, highlighting the value of these agents. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Conference fees: Gilead.
